Along with surgery, chemotherapy and irradiation of tumors in the foreground came out a new direction for the treatment of these diseases - the use of monoclonal antibodies.
Monoclonal antibodies are antibodies produced by cells of the immune system, having a common origin from the same precursor cell. You can develop practically against any antigen protein or polysaccharide nature. Further, by binding with the antigen, they can contribute to its detection, which is used in research to detect different substances, as well as for medical diagnosis. If antibody binding to certain pathogenic factor, deactivates it, then this property can be used for therapeutic purposes: monoclonal antibodies have been used in the treatment of malignant neoplasms in conjunction with other accepted methods.
Company Roche (Roche) was added to the Arsenal of cancer drug Avastin (Bevacizumab). Avastin binds to the growth factor vascular endothelial VEGF and deactivates it. Tumors of the rapid development of a vascular network, as its fast-growing cells require high amounts of nutrients, in addition, the vessels provide tumor cells is one of the ways of metastasis - spread throughout the body. Suppression of growth factor vessels in combination with traditional chemotherapy stops tumor growth with its further destruction, which helps to increase the life expectancy of cancer patients.
Avastin is not currently used for the treatment of children with oncological diseases, not due to the fact that it is contraindicated in young patients, but because those kinds of tumors, in which its use gives a therapeutic effect (tumor of the large intestine, lungs, kidneys, with certain histological characteristics), in children and adolescents is practically not observed.
But there is the possibility of applying balasuriya in the treatment of young patients suffering from other diseases. So, when retinopathy (pathological process in the retina) in premature infants, which is also observed increased growth of blood vessels, Avastin can be used with aggressive disease and inefficiency of laser therapy to prevent the onset of total blindness. Currently, the use of Avastin in pediatric ophthalmology is in the experimental stage, and it is not implemented in clinical practice.
Materials used http://www.roche.ru/home/produkzija/pharma/avastin.html